Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Small Molecules Studied
Download: Excel (XLSX), Comma-separated (CSV), Images (Zip file)
| HMS LINCS ID | Name | Alternative Names | LINCS ID | Structure Image | PubChem CID |
|---|---|---|---|---|---|
| 10251-1 | Fascaplysin | LSM-4272 |  | 73293 | |
| 10110-3 | FR180204 | FR 180204; KIN001-230 | LSM-42790 |  | 11493598 |
| 10508-1 | FTase Inhibitor I | B581 |  | 132887 | |
| 10098-2 | Gefitinib | ZD1839; Iressa | LSM-1098 |  | 123631 |
| 10108-2 | Geldanamycin | LSM-42789 |  | 644250 | |
| 10252-1 | Gemcitabine | Gemzar | LSM-5333 |  | 60750 |
| 10253-1 | Glycyl-H-1152 | LSM-4274 |  | ||
| 10062-3 | GSK1070916 | KIN001-216 | LSM-1062 |  | 46885626 |
| 10255-1 | GSK1838705A | LSM-4276 |  | 25182616 | |
| 10013-3 | GSK461364 | GSK461364A | LSM-1013 |  | 15983966 |
| 10257-1 | GSK923295 | LSM-4278 |  | 68651179 | |
| 10258-1 | Ibandronate | Boniva | LSM-4279 |  | 44828485 |
| 10259-1 | ICRF-193 | LSM-4280 |  | 115150 | |
| 10228-2 | IKK16 | LSM-2309 |  | 9549298 | |
| 10023-3 | Imatinib | Gleevec; Glivec; CGP-57148B; STI-571 | LSM-1023 |  | 5291 |
| 10260-1 | Ispinesib | SB-715992 | LSM-5732 |  | 6851740 |
| 10261-1 | Ixabepilone | Azaepothilone B; Ixempra | LSM-43293 |  | 216344 |
| 10208-2 | JNK-IN-5A | TCS JNK 5a; KIN001-188 | LSM-1209 |  | 766949 |
| 10262-1 | L-779450 | LSM-4283 |  | 9950176 | |
| 10051-3 | Lapatinib | GW-572016; Tykerb | LSM-1051 |  | 208908 |
| 10263-1 | LBH589 | Panobinostat | LSM-4284 |  | 57519507 |
| 10230-2 | Lestaurtinib | CEP-701 | LSM-1231 |  | 126565 |
| 10511-1 | Mebendazole | Vermox |  | 4030 | |
| 10264-1 | Methotrexate | Rheumatrex; Trexall; Amethopterin; MTX | LSM-5690 |  | 126941 |
| 10107 | MG-132 | LSM-1107 |  | 462382 |